Lukas C, Mary J, Debandt M, et al. - Individuals from the ESPOIR cohort with early inflammatory arthritis fulfilling the 2010 ACR/EULAR classification criteria for RA irrespective of negativity for both rheumatoid factor and anti-CCP antibodies were involved in order to ascertain predictors of good response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in seronegative RA people with early inflammatory arthritis. One hundred seventy-two cases were examined. Results imply that impediment at the beginning of csDMARD more than baseline clinical, biological, or imaging characteristics predominantly influences the outcome in early seronegative RA. These findings validate that to both seropositive and seronegative disease forms, the usual therapeutic notions in RA (early treatment, tight control, and treat-to-target) should be applied likewise.